Best GLP-1 for Sleep Apnea: Which Drug Improves OSA Most?

Which GLP-1 is best for obstructive sleep apnea?

Tirzepatide has the strongest evidence and is the only incretin medication FDA-approved specifically for obstructive sleep apnea (OSA). In December 2024 the FDA cleared tirzepatide (brand Zepbound) for moderate-to-severe OSA in adults with obesity, based on the SURMOUNT-OSA program. Other GLP-1 drugs can help OSA indirectly through weight loss, but only tirzepatide carries an OSA indication.

OSA improves with these drugs mainly because weight loss reduces the fatty tissue around the upper airway that contributes to airway collapse during sleep. The more weight a drug helps you lose, the more OSA tends to improve.

How much does tirzepatide reduce sleep apnea?

In the SURMOUNT-OSA trials published in the New England Journal of Medicine in 2024, tirzepatide produced a mean reduction in the apnea-hypopnea index (AHI) of up to about 62.8 percent versus placebo, which translated to roughly 27 to 30 fewer breathing events per hour of sleep. Participants lost about 18 to 20 percent of body weight. At the highest dose, 43.0 percent of participants in the study of people not using PAP and 51.5 percent in the study of people on PAP met criteria for disease resolution (Malhotra et al., NEJM, 2024).

This is the largest dedicated OSA drug trial of its kind, and it is why tirzepatide leads the field.

Does semaglutide work for sleep apnea?

Semaglutide is not FDA-approved for OSA, and there is no published dedicated semaglutide OSA trial. That said, semaglutide drives substantial weight loss (around 15 percent of body weight in the STEP obesity program), and weight loss is the main mechanism by which any of these drugs improves OSA. So semaglutide can reasonably be expected to help OSA indirectly, but the direct trial evidence sits with tirzepatide, not semaglutide.

Be skeptical of any source claiming a specific semaglutide "AHI reduction percentage" from a named OSA trial. That trial does not exist as of 2026. If a future dedicated semaglutide OSA trial is published, the picture could change, but right now the regulatory and trial evidence points to tirzepatide as the clear leader for sleep apnea, with semaglutide a reasonable weight-loss tool that may help OSA as a downstream effect.

What about liraglutide and other GLP-1 drugs?

Liraglutide (a daily GLP-1) has older OSA data from the SCALE obesity program, where it reduced AHI by a few events per hour more than placebo alongside modest weight loss. The effect is real but smaller than tirzepatide's, consistent with liraglutide's lower weight-loss potency. Dulaglutide and exenatide have weight-loss data but lack meaningful dedicated OSA evidence, so claims about exact AHI reductions for those drugs should be treated cautiously.

GLP-1 medications for sleep apnea compared

Medication	OSA approval	OSA evidence	Typical weight loss	Dosing
Tirzepatide	FDA-approved for OSA (2024)	SURMOUNT-OSA, strong	~18-20%	Weekly injection
Semaglutide	Not for OSA	Indirect via weight loss	~15%	Weekly injection
Liraglutide	Not for OSA	SCALE, modest	~5-8%	Daily injection
Dulaglutide	Not for OSA	Limited/indirect	~10-13%	Weekly injection
Exenatide	Not for OSA	Minimal	~5-7%	Daily/twice daily

How much weight loss do you need to improve OSA?

There is a well-established link between weight loss and AHI improvement. Research from the Wisconsin Sleep Cohort found that a 10 percent weight gain predicted roughly a 32 percent increase in AHI, and weight loss moved AHI in the favorable direction (Peppard et al., JAMA, 2000). In practice, meaningful OSA improvement usually tracks with losing at least 10 percent of body weight, and the larger losses seen with tirzepatide produce the largest AHI improvements.

This dose-response relationship is the simplest way to understand why tirzepatide outperforms the others on OSA: it produces the most weight loss, so it produces the most airway benefit. It also helps explain why GLP-1 drugs are not a fix for everyone with OSA. People whose sleep apnea is driven mainly by jaw or airway anatomy rather than weight may see less benefit, which is one more reason a sleep specialist should guide treatment.

Can you stop CPAP after starting a GLP-1?

Do not stop CPAP on your own. Even in the SURMOUNT-OSA program, where many patients improved substantially, CPAP decisions were made with follow-up sleep studies. Some people improve enough to reduce or discontinue PAP, but that should be confirmed by a sleep physician with a repeat study, not assumed from weight loss alone.

How FormBlends fits in

FormBlends is a telehealth platform that offers physician-supervised, compounded semaglutide and tirzepatide for weight management. Because OSA improvement is driven by weight loss, a supervised GLP-1 program can be part of an overall plan, but OSA itself needs evaluation and management by a sleep physician, including any decisions about CPAP. FormBlends does not replace sleep apnea diagnosis or CPAP. Compounded medications are prepared by licensed pharmacies and are not the same as the brand products.

Frequently asked questions

Is any GLP-1 FDA-approved for sleep apnea? Yes. Tirzepatide (Zepbound) was FDA-approved for moderate-to-severe OSA with obesity in December 2024. Others are not.

How much did tirzepatide reduce AHI in SURMOUNT-OSA? A mean reduction of up to about 62.8 percent versus placebo, roughly 27 to 30 fewer events per hour, with 18 to 20 percent weight loss.

Does semaglutide treat sleep apnea? It is not approved for OSA and has no dedicated OSA trial, but its weight loss can help OSA indirectly.

How long until OSA improves on a GLP-1? Improvement tracks weight loss, which builds over months. The trial outcomes were measured at 52 weeks.

Can I stop CPAP if I lose weight on a GLP-1? Only after a repeat sleep study and with your sleep physician's guidance.

What weight loss improves OSA most? Larger losses help more. At least 10 percent of body weight is a common threshold for meaningful improvement.

Does FormBlends treat sleep apnea? No. FormBlends offers compounded GLP-1 weight management. OSA must be diagnosed and managed by a sleep physician.

Sources

• Malhotra A. et al., Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity, NEJM 2024: https://www.nejm.org/doi/10.1056/NEJMoa2404881
• Eli Lilly, Tirzepatide reduced OSA severity, up to 51.5% met disease-resolution criteria: https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-reduced-obstructive-sleep-apnea-osa-severity
• FDA approval of Zepbound for OSA (Dec 2024), Lilly newsroom: https://investor.lilly.com/news-releases
• Peppard P.E. et al., Longitudinal study of moderate weight change and sleep-disordered breathing, JAMA 2000: https://pubmed.ncbi.nlm.nih.gov/11122588/
• SCALE program (liraglutide) obesity and OSA context, PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=liraglutide+obstructive+sleep+apnea+SCALE